Summit Therapeutics completes initial dosing trials on muscular dystrophy drug
Biopharmaceutical company Summit Therapeutics has completed an initial 24-week phase 2 clinical dosing trial of Ezutromid, its orally administered small molecule utrophin modulator, in patients with Duchenne muscular dystrophy (DMD).
FTSE AIM All-Share
740.92
08:55 19/04/24
Pharmaceuticals & Biotechnology
21,044.23
08:54 19/04/24
Summit Therapeutics
20.50p
16:55 21/02/20
Summit was expecting to report the results of the trial in the first quarter of 2018, with a biopsy, MRI and functional analyses planned for shortly thereafter.
The phase 2 trial was set to be conducted over a 48 week period and had as many as 40 patients enrolled across the US and the UK.
Dr David Roblin, chief operating officer and medical officer of Summit, said, "In the interim data readout, we aim to show a positive change following ezutromid treatment in muscle structure and health through the evaluation of muscle biopsies."
"The trial aims to establish proof of concept of Ezutromid and is evaluating a range of muscle structure, muscle health and functional endpoints.
"Each patient will have two muscle biopsies taken as part of the trial, including a baseline biopsy on enrolment and a second either after 24 weeks or 48 weeks of dosing," he concluded.
As of 1620 GMT, shares had gained 1.63% to 170.22p.